Skip to main content

Mitotane Not Needed With Low- to Intermediate-Risk Adrenocortical Carcinoma

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

TUESDAY, Sept. 5, 2023 -- Mitotane does not show a significant improvement in the relapse rate and is associated with adverse events in patients with adrenocortical carcinoma considered to be at low-to-intermediate risk for recurrence, according to a phase 3 study published online Aug. 21 in The Lancet Diabetes & Endocrinology.

Massimo Terzolo, M.D., from the University of Turin in Italy, and colleagues assessed the efficacy and safety of adjuvant mitotane (45 patients) versus surveillance alone (46 patients) following complete tumor resection in patients with adrenocortical carcinoma considered to be at low to intermediate risk for recurrence.

The researchers found that five-year recurrence-free survival was 79 percent in the mitotane group versus 75 percent in the surveillance group (hazard ratio, 0.74; 95 percent confidence interval [CI], 0.30 to 1.85). Five-year overall survival was not significantly different between the groups (95 versus 86 percent in the mitotane and surveillance groups). There were two deaths in the mitotane group and five in the surveillance group. Adverse events were seen in all 42 patients who received mitotane, and 19 percent discontinued treatment. The study was discontinued prematurely due to slow recruitment.

“Adjuvant mitotane might not be indicated in patients with low-grade, localized adrenocortical carcinoma considering the relatively good prognosis of these patients,” the authors write.

Two authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Read this next

Cabozantinib Promising for Advanced Adrenocortical Carcinoma

FRIDAY, April 26, 2024 -- For patients with advanced adrenocortical carcinoma, cabozantinib shows promising efficacy, according to a study published online April 9 in The Lancet...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.